Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

NCT01107717 on ClinicalTrials.gov · last registry update 2024-09-05

An unusually large phase 4: 318 participants, more than double the 75 typical for the stage. The sponsor logged completion for 3 February 2023. Primary outcome, as filed: HbA1c Level. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: The University of Texas Health Science Center at San Antonio
Sponsor type: Other
Enrollment: 318
Started: 2009-01
Primary completion: 2023-02-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c Level

Conditions studied

Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.